Form 4: OrbiMed Boosts Adicet Bio Stake with $5M Stock Purchase

OrbiMed Advisors and its affiliated entities acquired 5 million shares of Adicet Bio common stock for $5 million in a registered direct offering.

Summary

• OrbiMed Advisors LLC and its related entities, identified as a 10% owner of Adicet Bio, Inc. (ACET), reported significant purchases of common stock.
• On October 8, 2025, OrbiMed Private Investments V, LP (OPI V) acquired 1,500,000 shares of common stock at a price of $1 per share.
• On the same date, OrbiMed Private Investments VI, LP (OPI VI) acquired 3,500,000 shares of common stock at a price of $1 per share.
• These purchases were part of an underwritten registered direct offering, totaling 5,000,000 shares for $5,000,000.
• Following these transactions, OrbiMed's total indirect beneficial ownership in Adicet Bio, Inc. increased to 16,447,140 shares.
• The beneficial ownership is distributed across various OrbiMed funds: OrbiMed Israel Partners Limited Partnership (1,027,885 shares), OrbiMed Israel Partners II, L.P. (646,657 shares), OrbiMed Private Investments V, LP (9,026,359 shares), OrbiMed Private Investments VI, LP (4,490,254 shares), and OrbiMed Genesis Master Fund, L.P. (1,255,985 shares).

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to a significant insider purchase by a major institutional investor, signaling strong confidence in the company's value and future prospects.

Positives

• Significant insider buying by a major institutional investor (OrbiMed Advisors and affiliates) signals strong confidence in Adicet Bio's future prospects.
• The acquisition of 5 million shares for $5 million represents a substantial investment, increasing OrbiMed's total beneficial ownership to over 16.4 million shares.
• The participation in a direct offering indicates a strategic decision to increase exposure to Adicet Bio at a fixed price.

Future Outlook

NA

Industry Context

This transaction reflects a significant investment by a specialized healthcare investment firm, OrbiMed, into a biotechnology company. Such substantial purchases by institutional investors often indicate a positive long-term view on the company's pipeline or market position within the competitive biotech industry.

Stakeholder Impact

• Shareholders: Increased institutional ownership and a strong vote of confidence from a major investor could positively influence market perception and share price.
• Company: The direct offering provided $5 million in capital, which can be used for operations, research, or other strategic initiatives.

Key Dates

Recommendation

The substantial purchase of 5 million shares by OrbiMed Advisors and its affiliates, a sophisticated institutional investor and 10% owner, at a fixed price of $1 per share in a direct offering, represents a strong vote of confidence. Such significant insider buying often precedes positive developments or reflects a belief that the stock is undervalued, making it an attractive 'buy' signal for seasoned investors.

Keywords

Adicet Bio, ACET, OrbiMed Advisors, stock purchase, insider buying, SEC Form 4, beneficial ownership, direct offering, institutional investment